Session Details

SUN03 Pediatric Dermatology in Diverse Populations and Healthcare Settings

Fri, Aug 2, 7:30 AM - 8:30 AM
611
1 CME Available Sunrise Session NEW
View Map

DESCRIPTION

Literature suggests race, ethnicity, socioeconomic status, and gender diversity affect care in pediatric dermatology. This session will be a case-based discussion of the diagnosis, treatment, and management of pediatric skin disease (including vitiligo, acne, hidradenitis suppurativa, and psoriasis) in underserved and/or minority populations, including gender diverse populations, to better understand issues of healthcare equity and improve diagnosis and treatment in pediatric dermatology. The intended audience is dermatologists who encounter pediatric patients, with intent to provide increased exposure to presentation in diverse patients as well as to highlight disparities in access and care, ultimately to improve healthcare outcomes for vulnerable populations.

LEARNING OBJECTIVES

1.

Recognize and diagnose pediatric skin disease in marginalized populations, including racial, socioeconomic and gender minorities.

2.

Identify considerations for treatment of children and adolescents in resource-limited and community health settings.

3.

Discuss the impact of equity on the management of pediatric skin disease.

SCHEDULE

2:30 PM

Introduction

Anna Cristina Garza-Mayers, MD, PhD, FAAD

2:40 PM

Acne Treatment in Transgender and Gender Diverse Populations

Markus Boos, PhD, MD, FAAD

3:00 PM

Adolescents and Tools for Shared Decision Making in Hidradenitis Suppurativa and Other Diseases

George K Hightower, MD, FAAD

3:20 PM

Q&A

SPEAKERS

Markus Boos, PhD, MD, FAAD

Markus Boos, PhD, MD, FAAD

Anna Cristina Garza-Mayers, MD, PhD, FAAD

Anna Cristina Garza-Mayers, MD, PhD, FAAD

George K Hightower, MD, FAAD

George K Hightower, MD, FAAD

SPEAKER DISCLOSURES

Markus Boos, PhD, MD, FAAD

Regeneron Pharmaceuticals, Inc. – Investigator(No Compensation Received);

Anna Cristina Garza-Mayers, MD, PhD, FAAD

Sanofi/Regeneron – Advisory Board(Honoraria);

George K Hightower, MD, FAAD

No financial relationships exist with ineligible companies.